SOURCE: IntelliCell BioSciences

August 30, 2011 07:05 ET

IntelliCell BioSciences, Inc. Announces It Has Signed a Licensing Agreement With The PAWS Pet Company, Inc.

NEW YORK, NY--(Marketwire - Aug 30, 2011) - IntelliCell BioSciences, Inc. (OTCQX: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today that it has executed an agreement with The PAWS Pet Company, Inc., (OTCQB: PAWS) (PINKSHEETS: PAWS), the innovative pet services company. This collaboration will make SVF available to the veterinary world for use in the full-spectrum of pet applications.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells, the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments. In addition, numerous studies have been conducted on animals for veterinary applications over the last few decades.

"Our deal with The PAWS Pet Company is a very exciting advancement for veterinary medicine! With their marketing skills in the animal world and our advanced technology we have a winning formula for treating animals with 'IntelliCells' which has a high concentration of stem cells," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

Dan Wiesel, Chairman and CEO of The PAWS Pet Company, added, "We are excited to be working with IntelliCell to bring their regenerative medicine treatment to the pet marketplace. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets."

IntelliCell's adipose stem cell processing technique takes approximately 30 minutes and the stem cells can be returned to the veterinarian in the same day. Autologous Adipose stem cells are on the cutting edge of medicine and IntelliCell is excited to be one of the companies to participate in this field.

IntelliCell has developed an in-house technology where it can easily process stromal vascular cells containing a high concentration of adipose stem cells with excellent viability. At present, management believes it is the only company that does not use enzymes in processing adipose tissue and actually counts and checks the adipose stem cells they manufacture.

About IntelliCell Biosciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.

About The PAWS Pet Company

The PAWS Pet Company, Inc. provides innovative pet services. Its wholly owned subsidiary Pet Airways is the only airline specifically designed for the safe and comfortable transportation of pets. Pet Airways' Pawsengers™ travel in the specially equipped main cabin of its planes -- where pets are continuously monitored by an In-Flight Pet Attendant and the climate is controlled for maximum pet comfort. With Pet Airways, pet parents can be assured their pets will be treated with tender, loving care by pet professionals throughout the journey. The airline launched flight operations in 2009 and currently serves coast-to-coast destinations across the United States, including Los Angeles, Phoenix, Denver, Omaha, Chicago, Baltimore, New York, Atlanta and Ft. Lauderdale. The company has also announced its upcoming expansion to Orlando, Dallas, Austin, Houston and St. Louis.

For more information on The PAWS Pet Company go to www.thepawspetcompany.com

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact Information

  • Contacts

    Investor Relations for IntelliCell BioSciences Inc.
    Daria Schabad
    646. 810. 2183
    Email Contact